News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Certara Corporation Launches Cardiac Safety Simulator to Determine Likelihood That New Drug Candidates Could Cause Potentially-Fatal Arrhythmias


8/1/2013 11:21:18 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. LOUIS--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced the launch of its Cardiac Safety Simulator™ (CSS), based on an in-silico model of human ventricular heart cells. When the CSS is integrated with Certara’s Simcyp™ Population-based Simulator, it allows for the in-vitro to in-vivo extrapolation of the pharmacokinetic and pharmacodynamic data to predict the likelihood that a drug candidate will exhibit cardiac toxicity.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES